Biohaven Ltd. reports the FDA instructed it to pause new opakalim enrollment under a September 4, 2026 partial clinical hold; BHV-1300 entered Phase 3, while BHV-1400 Phase 3 initiation is planned for 2026.
BHVN · Biohaven Ltd.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 39%
- Last earnings
- May 27, 2026
- Latest filing
- 10-Q · Oct 29
- Price history
- Sep 2022 to Nov 2026
Up next
Latest documents
Biohaven's new drug application resubmission for Vyglxia (troriluzole) in spinocerebellar ataxia was accepted for review by the FDA, with a user fee goal date in the first quarter of 2027. The company reported a net loss of $129.3 million, or $0.86 per share, for the three months ended September 30, 2026. Cash, cash equivalents, marketable securities and restricted cash totaled approximately $164.0 million as of September 30, 2026.
In August 2026, Biohaven agreed to license its Kv7 ion channel platform, including BHV-7000, worldwide to SK Biopharmaceuticals. SKBP will pay a non-creditable and non-refundable upfront fee of $400.0 million, $350.0 million at Closing and $50.0 million one year later, plus up to $150.0 million in milestones. An FDA partial clinical hold dated September 4, 2026 pauses new patient enrollment pending additional metabolite nonclinical data.
Biohaven said the FDA accepted its troriluzole resubmission for spinocerebellar ataxia and set a user fee goal date in the first quarter of 2027. The FDA considers the resubmission a complete response to the November 4, 2025 action letter.
Biohaven entered a Collaboration and License Agreement with Ono Pharmaceutical granting Ono an exclusive, royalty-bearing license to its MoDE pan IgG degrader portfolio in Japan, South Korea, Taiwan and ASEAN countries. Ono will pay an $80 million upfront payment at closing and another $20 million upon a milestone achievement, plus royalties of approximately 20% on net sales. Biohaven keeps rights outside the territory, including the United States, Europe and China.
Metrics snapshot
Useful current figures from the complete screener profile.
Mentioned in fund letters
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| already randomized patients | 600 | to date | — |
| cash consideration | $400M | August 2026 | — |
| combined award | $4M | August 2026 | — |
| Non-GAAP adjusted net loss non-GAAP | $110.7M | three months ended September 30, 2026 | — |
| Non-GAAP adjusted net loss per share non-GAAP | $0.73 | three months ended September 30, 2026 | — |
| participants dosed to date | 1,200 | to date | — |
| upfront payment received to date | $80M | October 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BHVN
this stock
Biohaven Ltd.
|
$1.87B | +9.7% | — | — | 9.9% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$130.58B | +13.6% | +46.2% | 33.2 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.24B | +19.3% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$78.90B | +561.2% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$62.17B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 16, 2026
- This year
- 23
Biohaven Ltd. reports the FDA instructed it to pause new opakalim enrollment under a September 4, 2026 partial clinical hold; BHV-1300 entered Phase 3, while BHV-1400 Phase 3 initiation is planned for 2026.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BHVN | -10.4% | -10.7% | +22.3% | -19.7% | +9.7% |
| SPY | -8.6% | -9.2% | -9.2% | -8.7% | +1.2% |
| vs SPY | -1.8% | -1.5% | +31.5% | -10.9% | +8.6% |